2026

➢  JAMA Otolaryngology – Head & Neck Surgery – PredicineBEACON™, PredicineWES+™
Prognostic Value of Tumor-Informed Circulating Tumor DNA in HPV–Independent Head and Neck Squamous Cell Carcinoma

2025

➢  Clinical Cancer Research – PredicineBEACON™
Personalized MRD Assessment in Peri-surgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma

2024

➢  Journal of Liquid Biopsy – PredicineBEACON™, PredicineALERT™
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

➢  Nature Communications – PredicineCARE™, PredicineCARE™ Ultra, PredicineALERT™
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

2023

➢  Nature Medicine – PredicineBEACON™, PredicineWES+™
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

➢  New England Journal of Medicine – PredicineBEACON™, PredicineWES+™
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer

2026

➢  Histopathology – PredicineATLAS™
clinicopathological and molecular study of two unique cases with microglandular and acinar like breast carcinoma

➢  Nature Communications – PredicineCARE™
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer

➢  Nature Communications – PredicineCARE™
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

➢  Nature Communications – PredicineATLAS™
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

➢  Frontiers in Oncology– PredicineCARE™, PredineCARE Ultra™, PredicineSCORE™
Ultra-Sensitive Detection of Mutant KRAS in Circulating Tumor DNA Predicts Survival in Resectable Pancreatic Adenocarcinoma

2025

➢  Annals of Oncology – PredicineCARE™
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

➢  New England Journal of Medicine – PredicineCARE™
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

2024

➢  Journal of Clinical Oncology – PredicineCARE™
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

➢  Journal of Clinical Oncology – PredicineHEME™
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

➢  New England Journal of Medicine – PredicineCARE™
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

➢  Med – PredicineWES+™
Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancernary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer

➢  Diagnostics – PredicineCARE™
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages

➢  Nature Medicine – PredicineCARE™
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

➢  British Journal of Cancer – PredicineCARE™
Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer

➢  Scientific Reports – PredicineCARE™
Analytical evaluation of circulating tumor DNA sequencing assays

➢  Blood Advances – PredicineCARE™, PredicineHEME™
Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia

2023

➢  European Urology – PredicineCARE™
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma

➢  Société Internationale d’Urologie Journal – PredicineATLAS™
Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy

➢  JCO Clinical Cancer Informatics – PredicineCARE™
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer

➢  EBioMedicine – PredicineCARE™
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

➢  The American Journal of Surgical Pathology – PredicineCARE™
Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features

➢  Frontiers in Oncology – PredicineCARE™
Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

2022

➢  Nature Communications – PredicineATLAS™
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

➢  BMC Journal of Translational Medicine – PredicineCARE™
Identification of mutation patterns and circulating tumour DNA-derived prognostic markets in advanced breast cancer patients

➢  PLoS ONE – PredicineATLAS™
Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels

➢  Frontiers in Oncology – PredicineATLAS™
Germline Mutational Landscape in Chinese Patients with Advanced Breast Cancer

➢  The Lancet Gastroenterology Hepatology – PredicineATLAS™
Gemcitabine and Cisplatin Plus Durvalumad With or Without Tremelimumad in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open-Label, Single-Centre, Phase 2 Study

➢  Frontiers in Oncology – PredicineCARE™
Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer

➢  Scientific Reports – PredicineCARE™
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

➢  BMC Medicine – PredicineCARE™
Combined impact of lipidomic and genetic aberrations on clinicaloutcomes in metastatic castration-resistant prostate cancer

2021

➢  EBioMedicine – PredicineCARE™, PredicineRNA™
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

➢  The Journal of Urology – PredicineCARE™
Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

➢  Breast Cancer Research and Treatment – PredicineCARE™
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China

➢  European Urology – PredicineCARE™
Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial

➢  Cancer Management and Research – PredicineCARE™
Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

➢  JCO Precision Oncology – PredicineCARE™
Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

2020

➢  The Breast – PredicineCARE™
Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

➢  Blood – PredicineCARE™
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

➢  European Urology – PredicineCARE™, PredicineRNA™
Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

➢  EBioMedicine – PredicineCARE™
Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

➢  Chinese Journal of Cancer Research – PredicineATLAS™
Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

➢  Critical Reviews in Oncology – PredicineCARE™
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

2019

➢  Breast Cancer Research – PredicineCARE™
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer

2026

➢  Clinical Cancer Research – PredicineCARE™
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer

➢  Clinical Cancer Research – PredicineATLAS™
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma

➢  Nature Communications – PredicineCARE™
Efficacy and safety of cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer (LungCadX): a multicenter, open-label, phase II trial

➢  Clinical and translational medicine – PredicineEPIC™
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2-overexpressing:
Preliminary results of a prospective, single-arm, phase II study

2025

➢  Clinical Cancer Research – PredicineBEACON™
Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient at a time

➢  Neuro-Oncology Advances – PredicineCARE™, PredicineSCORE™
Cerebrospinal fluid cell-free DNA as a liquid biopsy tool for detecting and monitoring genomic alterations in thalamic colorectal cancer metastases

➢  Neoplasia – PredicineCARE™
Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study

2024

➢  Journal of Liquid Biopsy – PredicineBEACON™, PredicineALERT™
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer

➢  Journal of Thoracic Oncology – PredicineEPIC™
High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases:A prospective real-world study

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

➢  Nature Communications – PredicineCARE™, PredicineCARE™ Ultra, PredicineALERT™
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

➢  Breast Cancer Research & Treatment – PredicineCARE™
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer

2023

➢  Nature Medicine – PredicineBEACON™, PredicineWES+™
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

➢  New England Journal of Medicine – PredicineBEACON™, PredicineWES+™
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer

➢  Journal of Pathology – PredicineATLAS™
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial

➢  Clinical Cancer Research – PredicineWES+™, PredicineSCORE™
Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer

2026

➢  The Journal of Clinical Investigation – PredicineWGS™
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models

2025

➢  Neuro-Oncology Advances – PredicineCARE™, PredicineSCORE™
Cerebrospinal fluid cell-free DNA as a liquid biopsy tool for detecting and monitoring genomic alterations in thalamic colorectal cancer metastases

➢  Biological Procedures Online – PredicineCARE™, PredicineEPIC™
A Rare Case of Long-Term Survival in Stage IIIB Lung Adenocarcinoma: an 9-Year Follow-Up

➢  Blood Advances – PredicineHEME™
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

➢  EJNMMI – PredicineWES+™
Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases

➢  UroPrecision – PredicineWES+™
Exome‐wide molecular insights from blood and urine liquid biopsies in genitourinary cancers

2024

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

➢  Nature Communications – PredicineCARE™, PredicineCARE™ Ultra, PredicineALERT™
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

2023

➢  Nature Medicine – PredicineBEACON™, PredicineWES+™
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

➢  New England Journal of Medicine – PredicineBEACON™, PredicineWES+™
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

2022

➢  The Lancet – PredicineHEME™
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

2021

➢  Frontiers in Oncology – PredicineCARE™, PredicineSCORE™
Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

All Publications

2026:

➢  Journal of Clinical Oncology – PredicineEPIC™
First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial

➢  Histopathology – PredicineATLAS™
clinicopathological and molecular study of two unique cases with microglandular and acinar like breast carcinoma

➢  Clinical Epigenetics – PredicineEPIC™
Development, characterization, and inter-laboratory validation of methylated human cell free DNA candidate reference materials

➢  Clinical Genitourinary Cancer – PredicineCARE™
A Real-World Prospective Study of Comprehensive Genomic Testing in Patients with Metastatic Castration-Resistant Prostate Cancer

➢  Clinical Cancer Research – PredicineATLAS™
Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma

➢  Nature Communications – PredicineCARE™
Efficacy and safety of cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer (LungCadX): a multicenter, open-label, phase II trial

➢  Clinical and translational medicine – PredicineEPIC™
Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2-overexpressing:
Preliminary results of a prospective, single-arm, phase II study

➢  Nature Communications – PredicineCARE™
ctDNA and tumor-based biomarkers of giredestrant response in acelERA breast cancer

➢  Nature Communications – PredicineCARE™
Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial

➢  Nature Communications – PredicineATLAS™
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma

➢  The Journal of Clinical Investigation – PredicineWGS™
Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models

➢  JAMA Otolaryngology – Head & Neck Surgery – PredicineBEACON™, PredicineWES+™
Prognostic Value of Tumor-Informed Circulating Tumor DNA in HPV–Independent Head and Neck Squamous Cell Carcinoma

➢  Clinical Cancer Research: – PredicineCARE™
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer

➢  Frontiers in Oncology – PredicineCARE™, PredicineCARE™ Ultra, PredicineSCORE™
Ultra-Sensitive Detection of Mutant KRAS in Circulating Tumor DNA Predicts Survival in Resectable Pancreatic Adenocarcinoma

2025:

➢  Annals of Oncology – PredicineCARE™
Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer

➢  Clinical Cancer Research – PredicineBEACON™
Personalized MRD Assessment in Peri-surgical ctDNA for Prognostic Prediction in Hepatocellular Carcinoma

➢  Clinical Cancer Research – PredicineCARE™, PredicineSCORE™
Longitudinal glioma monitoring via cerebrospinal fluid cell-free DNA: one patient at a time

➢  Neuro-Oncology Advances – PredicineCARE™, PredicineSCORE™
Cerebrospinal fluid cell-free DNA as a liquid biopsy tool for detecting and monitoring genomic alterations in thalamic colorectal cancer metastases

➢  Biological Procedures Online – PredicineCARE™, PredicineEPIC™
A Rare Case of Long-Term Survival in Stage IIIB Lung Adenocarcinoma: an 9-Year Follow-Up

➢  Neoplasia – PredicineCARE™
Disitamab vedotin combined with toripalimab and radiotherapy for multimodal organ-sparing treatment of muscle invasive bladder cancer: a proof-of-concept study

➢  New England Journal of Medicine – PredicineCARE™
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

➢  Blood Advances – PredicineHEME™
Acquired mutations in patients with relapsed/refractory CLL who progressed in the ALPINE study

➢  EJNMMI – PredicineWES+™
Homologous recombination repair gene alteration is strongly associated with more prostate-specific membrane antigen-positive metastases in newly diagnosed hormone-sensitive prostate cancer with ≤5 conventional imaging defined distant metastases

➢  UroPrecision – PredicineWES+™
Exome‐wide molecular insights from blood and urine liquid biopsies in genitourinary cancers

2024:

➢  Journal of Clinical Oncology – PredicineCARE™
Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study

➢  Journal of Clinical Oncology – PredicineHEME™
Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA

➢  New England Journal of Medicine – PredicineCARE™
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

➢  Journal of Liquid Biopsy – PredicineBEACON™, PredicineALERT™
Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer

➢  Journal of Thoracic Oncology – PredicineEPIC™
High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases:A prospective real-world study

➢  Clinical Cancer Research – PredicineCARE™, PredicineRNA™
High-dose Furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases:A prospective real-world study

➢  Med – PredicineWES+™
Interlesional response heterogeneity is associated with the prognosis of abiraterone treatment in metastatic castration-resistant prostate cancernary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

➢  Nature Communications – PredicineCARE™, PredicineCARE™ Ultra, PredicineALERT™
Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma

➢  Diagnostics – PredicineCARE™
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages

➢  Nature Medicine – PredicineCARE™
Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

➢  British Journal of Cancer – PredicineCARE™
Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer

➢  Scientific Reports – PredicineCARE™
Analytical evaluation of circulating tumor DNA sequencing assays

➢  Blood Advances – PredicineCARE™, PredicineHEME™
Biomarker analysis of the ASPEN study comparing zanubrutinib to ibrutinib in patients with Waldenström Macroglobulinemia

➢  Breast Cancer Research & Treatment – PredicineCARE™
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer

2023:

➢  Nature Medicine – PredicineBEACON™, PredicineWES+™
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial

➢  European Urology – PredicineCARE™
Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non–organ-confined Upper Tract Urothelial Carcinoma

➢  New England Journal of Medicine – PredicineBEACON™, PredicineWES+™
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation

➢  Clinical Cancer Research – PredicineBEACON™, PredicineWES+™
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer

➢  Journal of Pathology – PredicineATLAS™
Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial

➢  Société Internationale d’Urologie Journal – PredicineATLAS™
Utilizing Cell-Free Urinary and Plasma Tumor DNA to Predict Pathologic Stage at Radical Cystectomy

➢  JCO Clinical Cancer Informatics – PredicineCARE™
Multi-Omic Integration of Blood-Based Tumor-Associated Genomic and Lipidomic Profiles Using Machine Learning Models in Metastatic Prostate Cancer

➢  EBioMedicine – PredicineCARE™
BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype

➢  The American Journal of Surgical Pathology – PredicineCARE™
Triple-negative Breast Carcinoma With Apocrine and Histiocytoid features

➢  Frontiers in Oncology – PredicineCARE™
Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients

➢  Genes Chromosomes Cancer – PredicineATLAS™
Development and validation of blood tumor mutational burden reference standards

➢  Clinical Cancer Research – PredicineWES+™, PredicineSCORE™
Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer

2022:

➢  The Lancet – PredicineHEME™
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

➢  Nature Communications – PredicineATLAS™
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

➢  BMC Journal of Translational Medicine – PredicineCARE™
Identification of mutation patterns and circulating tumour DNA-derived prognostic markets in advanced breast cancer patients

➢  PLoS ONE – PredicineATLAS™
Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panels

➢  Frontiers in Oncology – PredicineATLAS™
Germline Mutational Landscape in Chinese Patients with Advanced Breast Cancer

➢  The Lancet Gastroenterology Hepatology – PredicineATLAS™
Gemcitabine and Cisplatin Plus Durvalumad With or Without Tremelimumad in Chemotherapy-Naive Patients with Advanced Biliary Tract Cancer: An Open-Label, Single-Centre, Phase 2 Study

➢  Frontiers in Oncology – PredicineCARE™
Urine- and Blood-Based Molecular Profiling of Human Prostate Cancer

➢  Scientific Reports – PredicineCARE™
Dynamic changes in gene alterations during chemotherapy in metastatic castrate resistant prostate cancer

➢  BMC Medicine – PredicineCARE™
Combined impact of lipidomic and genetic aberrations on clinicaloutcomes in metastatic castration-resistant prostate cancer

2021:

➢  EBioMedicine – PredicineCARE™, PredicineRNA™
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase

➢  Breast Cancer Research and Treatment – PredicineCARE™
Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China

➢  The Journal of Urology – PredicineCARE™
Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer

➢  European Urology – PredicineCARE™
Avelumab combined with stereotactic ablative body radiotherapy (SABR) in metastatic castration-resistant prostate cancer (mCRPC): the phase 2 ICE-PAC clinical trial

➢  Frontiers in Oncology – PredicineCARE™, PredicineSCORE™
Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer

➢  Fortune Journals – PredicineATLAS™
Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients

➢  Cancer Management and Research – PredicineCARE™
Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing

➢  JCO Precision Oncology – PredicineCARE™
Plasma Cell–Free DNA Profiling of PTEN-PI3K-AKT Pathway Aberrations in Metastatic Castration-Resistant Prostate Cancer

2020:

➢  The Breast – PredicineCARE™
Peripheral cytotoxic T lymphocyte predicts first-line progression free survival in HER2-positive advanced breast cancer

➢  Blood – PredicineCARE™
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

➢  European Urology – PredicineCARE™, PredicineRNA™
Combined cell-free DNA and RNA profiling of the androgen receptor: clinical utility of a novel multi-analyte liquid biopsy assay for metastatic prostate cancer

➢  EBioMedicine – PredicineCARE™
Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer

➢  Chinese Journal of Cancer Research – PredicineATLAS™
Efficacy of platinum in advanced triple-negative breast cancer (TNBC) with germline BRCA mutation determined by next generation sequencing

➢  Critical Reviews in Oncology – PredicineCARE™
Performance of a novel Next Generation Sequencing circulating tumor DNA (ctDNA) platform for the evaluation of samples from patients with metastatic breast cancer (MBC)

2019:

➢  Breast Cancer Research – PredicineCARE™
Association of a novel circulating tumor DNA next-generating sequencing platform with circulating tumor cells (CTCs) and CTC clusters in metastatic breast cancer